MAPT and Alzheimer disease: Our data show that 12-month-old Mertk-/- mice exhibit approximately 40% lower phosphorylated tau levels than WT mice, with no change in total tau, suggesting a role for Mertk in AD development via tau phosphorylation and consequent cognitive decline.